SG11201909825VA - Hsp90 inhibitor oral formulations and related methods - Google Patents
Hsp90 inhibitor oral formulations and related methodsInfo
- Publication number
- SG11201909825VA SG11201909825VA SG11201909825VA SG11201909825VA SG 11201909825V A SG11201909825V A SG 11201909825VA SG 11201909825V A SG11201909825V A SG 11201909825VA SG 11201909825V A SG11201909825V A SG 11201909825VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- capsules
- encapsulate
- november
- april
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 November 2018 (01.11.2018) WIPO I PCT IiiimmoimiolollmonolooloionsiollommovoimIE (10) International Publication Number WO 2018/200534 Al (51) International Patent Classification: A61K 9/20 (2006.01) A61K 31/52 (2006.01) A61K 9/22 (2006.01) A61K 31/7036 (2006.01) A61K 31/33 (2006.01) CO7D 473/32 (2006.01) A61K 31/395 (2006.01) CO7D 473/34 (2006.01) (21) International Application Number: PCT/US2018/029157 (22) International Filing Date: 24 April 2018 (24.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/489,438 24 April 2017 (24.04.2017) US 62/489,434 24 April 2017 (24.04.2017) US 62/532,985 14 July 2017 (14.07.2017) US 62/532,987 14 July 2017 (14.07.2017) US 62/588,893 20 November 2017 (20.11.2017) US 62/588,897 20 November 2017 (20.11.2017) US 62/627,229 07 February 2018 (07.02.2018) US 62/627,237 07 February 2018 (07.02.2018) US (71) Applicant: SAMUS THERAPEUTICS, INC. [US/US]; 10 South Main Street, Topsfield, MA 01983 (US). (72) Inventor: AMEDIO, John; 6 Ginny Lane, Franklin, MA 02038 (US). (74) Agent: TREVISAN, Maria, A.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = (54) Title: HSP90 INHIBITOR ORAL FORMULATIONS AND RELATED METHODS Final Blend Compression Delayed Release Coating Encapsulate: DR Capsules Encapsulate: DR Capsules Encapsulate: DR Capsules Encapsulate: DR Capsules PG. 1 (57) : Provided herein are novel and improved oral formulations for Hsp90 inhibitors. C ug Substance/Excipients Blend Mg Stearate [Continued on next page] WO 2018/200534 Al MIDEDIMOMMIDIRE101001010111MEIIINHEMOVOIS MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762489434P | 2017-04-24 | 2017-04-24 | |
US201762489438P | 2017-04-24 | 2017-04-24 | |
US201762532987P | 2017-07-14 | 2017-07-14 | |
US201762532985P | 2017-07-14 | 2017-07-14 | |
US201762588897P | 2017-11-20 | 2017-11-20 | |
US201762588893P | 2017-11-20 | 2017-11-20 | |
US201862627229P | 2018-02-07 | 2018-02-07 | |
US201862627237P | 2018-02-07 | 2018-02-07 | |
PCT/US2018/029157 WO2018200534A1 (en) | 2017-04-24 | 2018-04-24 | Hsp90 inhibitor oral formulations and related methods |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201909825VA true SG11201909825VA (en) | 2019-11-28 |
Family
ID=63918615
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913562VA SG10201913562VA (en) | 2017-04-24 | 2018-04-24 | Hsp90 inhibitor oral formulations and related methods |
SG11201909825V SG11201909825VA (en) | 2017-04-24 | 2018-04-24 | Hsp90 inhibitor oral formulations and related methods |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913562VA SG10201913562VA (en) | 2017-04-24 | 2018-04-24 | Hsp90 inhibitor oral formulations and related methods |
Country Status (11)
Country | Link |
---|---|
US (1) | US20200069592A1 (en) |
EP (1) | EP3615008A4 (en) |
JP (1) | JP2020517732A (en) |
KR (1) | KR20190138871A (en) |
CN (1) | CN110996918A (en) |
AU (2) | AU2018257901A1 (en) |
CA (1) | CA3061185A1 (en) |
IL (1) | IL296355A (en) |
SG (2) | SG10201913562VA (en) |
TW (1) | TWI782982B (en) |
WO (1) | WO2018200534A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200019220A (en) * | 2017-06-23 | 2020-02-21 | 사무스 테라퓨틱스, 인코포레이티드 | Epichaperom Inhibitor Therapy for Traumatic Brain Injury and Sequelae thereof |
WO2020243393A1 (en) * | 2019-05-30 | 2020-12-03 | Vta Labs, Llc | Design of a single oral delivery system containing a monoclonal antibody for the simultaneous treatment of chron's disease and ulcerative colitis |
CN114259564B (en) * | 2021-11-30 | 2023-03-14 | 清华大学 | Novel use of HSP90 inhibitors for blocking STAT3 mitochondrial transport and for treating asthma |
US12042491B1 (en) * | 2022-12-30 | 2024-07-23 | Tap Pharmaceuticals Ag | Pharmaceutical formulations of quinolines |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006130469A1 (en) * | 2005-05-27 | 2006-12-07 | Oregon Health & Science University | Stimulation of neurite outgrowth by small molecules |
DK2034839T3 (en) * | 2006-06-30 | 2017-12-04 | Sloan-Kettering Institute For Cancer Res | TREATMENT OF NEURODEGENERATIVE DISEASES BY INHIBITION OF HSP90 |
PE20081506A1 (en) * | 2006-12-12 | 2008-12-09 | Infinity Discovery Inc | ANSAMYCIN FORMULATIONS |
TW200904405A (en) * | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Pharmaceutical formulations containing an SGLT2 inhibitor |
MX2010008269A (en) * | 2008-02-01 | 2011-02-21 | Takeda Pharmaceutical | Oxim derivatives as hsp90 inhibitors. |
US8309578B2 (en) * | 2008-11-25 | 2012-11-13 | Nerviano Medical Sciences S.R.L. | Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents |
CA2776308C (en) * | 2009-10-07 | 2020-01-28 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
JP5784623B2 (en) * | 2009-11-13 | 2015-09-24 | アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag | Rapid release tablet formulation |
WO2011060253A2 (en) * | 2009-11-13 | 2011-05-19 | Myrexis, Inc. | Methods of treating diseases, pharmaceutical compositions, and pharmaceutical dosage forms |
US8603527B2 (en) * | 2010-10-25 | 2013-12-10 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations of a substituted diaminopurine |
WO2012131413A1 (en) * | 2011-03-25 | 2012-10-04 | Debiopharm Sa | Crystalline forms of fused amino pyridines as hsp90 inhibitors |
JP2015525063A (en) * | 2012-05-16 | 2015-09-03 | シンタ ファーマスーティカルズ コーポレーション | Pre-selection of subjects for treatment with HSP90 inhibitors based on hypoxia |
CA2874676A1 (en) * | 2012-05-25 | 2013-11-28 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta |
AU2014228822A1 (en) * | 2013-03-15 | 2015-10-01 | Memorial Sloan-Kettering Cancer Center | HSP90-targeted cardiac imaging and therapy |
UA115815C2 (en) * | 2013-07-30 | 2017-12-26 | Гіліад Коннектікут, Інк. | COMPOSITION BASED ON SYK INHIBITORS |
US10758526B2 (en) * | 2014-06-09 | 2020-09-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health | Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways |
TW201609108A (en) * | 2014-07-25 | 2016-03-16 | 諾華公司 | Pharmaceutical dosage forms |
MX2017001671A (en) * | 2014-08-07 | 2017-07-04 | Pharmacyclics Llc | Novel formulations of a bruton's tyrosine kinase inhibitor. |
CN104173283B (en) * | 2014-08-27 | 2016-09-07 | 广州暨南生物医药研究开发基地有限公司 | A kind of nano suspension of Hsp90 inhibitor with benzamide as basic framework and preparation method thereof |
KR20200019220A (en) * | 2017-06-23 | 2020-02-21 | 사무스 테라퓨틱스, 인코포레이티드 | Epichaperom Inhibitor Therapy for Traumatic Brain Injury and Sequelae thereof |
-
2018
- 2018-04-24 JP JP2019559089A patent/JP2020517732A/en active Pending
- 2018-04-24 CA CA3061185A patent/CA3061185A1/en active Pending
- 2018-04-24 US US16/607,610 patent/US20200069592A1/en not_active Abandoned
- 2018-04-24 CN CN201880040143.1A patent/CN110996918A/en active Pending
- 2018-04-24 KR KR1020197034522A patent/KR20190138871A/en not_active Application Discontinuation
- 2018-04-24 AU AU2018257901A patent/AU2018257901A1/en not_active Abandoned
- 2018-04-24 SG SG10201913562VA patent/SG10201913562VA/en unknown
- 2018-04-24 TW TW107113882A patent/TWI782982B/en active
- 2018-04-24 SG SG11201909825V patent/SG11201909825VA/en unknown
- 2018-04-24 IL IL296355A patent/IL296355A/en unknown
- 2018-04-24 WO PCT/US2018/029157 patent/WO2018200534A1/en unknown
- 2018-04-24 EP EP18790960.1A patent/EP3615008A4/en not_active Withdrawn
-
2022
- 2022-10-18 AU AU2022256110A patent/AU2022256110A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TWI782982B (en) | 2022-11-11 |
CN110996918A (en) | 2020-04-10 |
US20200069592A1 (en) | 2020-03-05 |
IL296355A (en) | 2022-11-01 |
EP3615008A1 (en) | 2020-03-04 |
CA3061185A1 (en) | 2018-11-01 |
WO2018200534A1 (en) | 2018-11-01 |
EP3615008A4 (en) | 2021-05-05 |
AU2022256110A1 (en) | 2022-11-17 |
SG10201913562VA (en) | 2020-03-30 |
TW201904564A (en) | 2019-02-01 |
AU2018257901A1 (en) | 2019-11-14 |
KR20190138871A (en) | 2019-12-16 |
JP2020517732A (en) | 2020-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201804915RA (en) | Methods for treating huntington's disease | |
SG11201907023UA (en) | Method of reducing neutropenia | |
SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201909825VA (en) | Hsp90 inhibitor oral formulations and related methods | |
SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
SG11201809534UA (en) | Methods of treating autoimmune disease using allogeneic t cells | |
SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201907420VA (en) | Inhibition of smarca2 for treatment of cancer | |
SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201900214UA (en) | Iso-citrate dehydrogenase (idh) inhibitor | |
SG11201810934TA (en) | Microparticles comprising a sulphur-containing compound | |
SG11201909906QA (en) | Organic compounds | |
SG11201809541UA (en) | Immune checkpoint inhibitors and cytotoxic t cells for the treatment of cancer |